Pfizer Inc.
In the published model solve dated 2026-Q2, anchored at $27.96, Pfizer Inc. (PFE) is priced for -2.9% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed August 7, 2026 from SEC EDGAR filings.
• Pfizer tells shareholders directly that revenue lost to expiring patents will keep falling through 2030 and that the pace of the decline will accelerate, and that single sentence organizes everything else about the company [Source: FY2025 Form 10-K]. • Against that, the products it has launched or acquired recently grew 18 percent operationally in the quarter ended June 28, 2026, and management lifted the midpoint of full-year revenue guidance to 61.5 billion dollars [Source: Q2 2026 earnings
Is PFE overvalued? See what's priced in →
2,864 institutional managers reported holding PFE in 13F filings for the quarter ended 2026-03-31. Together they hold about 65% of the company; the top 10 hold 33%. 197 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 162.1M shares were sold short as of the 2026-06-15 count, about 3% of shares outstanding (4.6 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
PFE's share count grew 1.7% over the past five years even with $2.00B spent on repurchases. It pays a dividend, and has paid one every year in our records (18 and counting), raised 15 years straight; the current rate is $1.72 a share annually. Cash returned over the past three years: $26.36B in dividends.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at PFE over the trailing three years: 2023: 1 buy totaling $79k; 2024: 1 buy totaling $28k; 2025: 1 buy totaling $499k. 11 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
PFE's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-10 | -2.0% | -7.8% |
| 2023-11-09 | -0.1% | -4.3% |
| 2024-02-23 | -1.5% | -8.5% |
| 2024-05-09 | +8.1% | +1.7% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
PFE's latest 8-K filings: 2026-08-04 (items 2.02, 9.01); 2026-06-18 (items 7.01); 2026-06-18 (items 5.02, 9.01); 2026-05-05 (items 2.02, 9.01); 2026-04-27 (items 5.07).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: August 7, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.